title: Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial.
abstract: OBJECTIVE
  To study whether intravitreal dexamethasone as adjuvant to intravitreal antibiotics improves the outcome in patients with suspected postoperative bacterial endophthalmitis.
  
  
  METHODS
  Prospective randomized clinical trial.
  
  
  METHODS
  Tertiary referral center.
  
  
  METHODS
  Twenty-nine consecutive patients with suspected postoperative bacterial endophthalmitis within 6 weeks of cataract surgery.
  
  
  METHODS
  Patients underwent a vitreous biopsy followed by intravitreal injection of antibiotics (0.2 mg vancomycin and 0.05 mg gentamicin) and 400 microg dexamethasone or placebo. After 3-4 days the intravitreal injection of antibiotics and dexamethasone or placebo was repeated.
  
  
  METHODS
  Snellen visual acuity at 3 and 12 months after treatment.
  
  
  RESULTS
  In 20/29 patients (69%) the vitreous cultures were positive. 13/29 patients received dexamethasone. Seven patients had a functionally lost eye (final vision of hand movements or less), in four due to retinal detachment. Visual acuity tended to be better in the dexamethasone treated patients than in those given placebo, at both 3 months (P=0.055) and 12 months (P=0.080).
  
  
  CONCLUSIONS
  This small prospective, placebo-controlled series showed a trend towards a better visual outcome in patients with suspected bacterial endophthalmitis when treatment with intravitreal antibiotics was combined with intravitreal dexamethasone. Our findings justify a larger multicenter randomized study.
authors.affiliation: The Rotterdam Eye Hospital, The Netherlands.
authors.forename: Ivan M
authors.initials: IM
authors.lastname: Gan
authors.forename: Luana C
authors.initials: LC
authors.lastname: Ugahary
authors.forename: Jaap T
authors.initials: JT
authors.lastname: van Dissel
authors.forename: Eric
authors.initials: E
authors.lastname: Feron
authors.forename: Ed
authors.initials: E
authors.lastname: Peperkamp
authors.forename: Marc
authors.initials: M
authors.lastname: Veckeneer
authors.forename: Paul G H
authors.initials: PG
authors.lastname: Mulder
authors.forename: Gert Jan
authors.initials: GJ
authors.lastname: Platenkamp
authors.forename: Jan C
authors.initials: JC
authors.lastname: van Meurs
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001706:Biopsy; D002387:Cataract Extraction / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D003907:Dexamethasone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000188:drug therapy* / Q000209:etiology; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D005839:Gentamicins / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011446:Prospective Studies; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use; D014822:Vitreous Body / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D005938:Glucocorticoids; D014640:Vancomycin; D003907:Dexamethasone